ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Interactive Brokers

Interactive Brokers
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
S&P 500
5,235.48
-0.60%
US Tech 100
18,017.60
-1.31%
Dow Jones
38,111.48
-0.86%
Brent Oil
81.725
-0.27%
Bitcoin
68,403.96
0.06%
Registration Strip Icon for tools Level up your trading with our powerful tools and real-time insights all in one place.
Get Started
Symbol: 
Date:
Sort by:
DateTimeSourceHeadlineSymbolCompany
05/31/20241:00AMGlobeNewswire Inc.VEON discloses April YTD trading update at its AGMEU:VEONVEON Ltd
05/31/20241:00AMBusiness WireElliptic Labs Launching on Upcoming vivo S19 and S19 Pro Smartphones
05/31/20241:00AMGlobeNewswire Inc.Issue of Additional Tier 1 Temporary Write-Down Notes
05/31/20241:00AMGlobeNewswire Inc.VEON discloses April YTD trading update at its AGMLSE:0RO7Veon Ltd
05/31/20241:00AMGlobeNewswire Inc.Addex Therapeutics to Release Q1 2024 Financial Results and Host Conference Call on June 6, 2024NASDAQ:ADXNAddex Therapeutics Ltd
05/31/20241:00AMGlobeNewswire Inc.VEON discloses April YTD trading update at its AGMNASDAQ:VEONVEON Ltd
05/31/20241:00AMGlobeNewswire Inc.VEON discloses April YTD trading update at its AGMTG:35V1VEON Ltd
05/31/20241:00AMGlobeNewswire Inc.BioSenic S.A. : Information relative au nombre total de droits de vote et d’actionsLSE:0R55Biosenic Sa
05/31/20241:00AMGlobeNewswire Inc.BioSenic S.A. : Information on the total number of voting rights and sharesLSE:0R55Biosenic Sa
05/31/20241:00AMGlobeNewswire Inc.Press Release: Update on FDA priority review of Dupixent for the treatment of COPD patients with type 2 inflammationEU:SANSanofi
05/31/20241:00AMGlobeNewswire Inc.Update on FDA Priority Review of Dupixent® (dupilumab) for the Treatment of COPD Patients with Type 2 InflammationNASDAQ:SNYSanofi
05/31/20241:00AMGlobeNewswire Inc.Communiqué de presse : Point d’actualité sur l’examen prioritaire de la FDA relatif au Dupixent pour le traitement de la BPCO avec inflammation de type 2EU:SANSanofi
05/31/20241:00AMGlobeNewswire Inc.Communiqué de presse : Point d’actualité sur l’examen prioritaire de la FDA relatif au Dupixent pour le traitement de la BPCO avec inflammation de type 2BIT:SANFSanofi
05/31/20241:00AMGlobeNewswire Inc.Press Release: Update on FDA priority review of Dupixent for the treatment of COPD patients with type 2 inflammationEU:SANSanofi
05/31/20241:00AMGlobeNewswire Inc.Communiqué de presse : Point d’actualité sur l’examen prioritaire de la FDA relatif au Dupixent pour le traitement de la BPCO avec inflammation de type 2BIT:1SANSanofi
05/31/20241:00AMGlobeNewswire Inc.Press Release: Update on FDA priority review of Dupixent for the treatment of COPD patients with type 2 inflammationBIT:SANFSanofi
05/31/20241:00AMGlobeNewswire Inc.BioSenic S.A. : Information relative au nombre total de droits de vote et d’actionsEU:BIOSBiosenic
05/31/20241:00AMGlobeNewswire Inc.BioSenic S.A. : Information on the total number of voting rights and sharesEU:BIOSBiosenic
05/31/20241:00AMGlobeNewswire Inc.Start of Day Message
05/31/20241:00AMGlobeNewswire Inc.Press Release: Update on FDA priority review of Dupixent for the treatment of COPD patients with type 2 inflammationBIT:1SANSanofi
05/31/20241:00AMGlobeNewswire Inc.Press Release: Update on FDA priority review of Dupixent for the treatment of COPD patients with type 2 inflammationTG:SNWSanofi
05/31/20241:00AMGlobeNewswire Inc.Update on FDA Priority Review of Dupixent® (dupilumab) for the Treatment of COPD Patients with Type 2 InflammationSAN.PA
05/31/20241:00AMGlobeNewswire Inc.Update on FDA Priority Review of Dupixent® (dupilumab) for the Treatment of COPD Patients with Type 2 InflammationNASDAQ:REGNRegeneron Pharmaceuticals Inc
05/31/20241:00AMGlobeNewswire Inc.Communiqué de presse : Point d’actualité sur l’examen prioritaire de la FDA relatif au Dupixent pour le traitement de la BPCO avec inflammation de type 2TG:SNWSanofi
05/31/20241:00AMPR Newswire (US)Linda Mack of Mack International was a panelist for the Palm Beach Family Office Forum sponsored by Day Pitney on May 7th, 2024
05/31/202412:56AMAlliance NewsAlliance News*ANZ sells remaining 5.2% shareholding in AmBank
05/31/202412:45AMAlliance NewsAlliance NewsDonald Trump convicted on all charges in hush money trial
05/31/202412:45AMAlliance NewsAlliance NewsUK retail footfall remains down despite bank holidays and sun
05/31/202412:43AMAlliance NewsAlliance NewsChina factory activity contracts for first time in three months
05/31/202412:42AMGlobeNewswire Inc.Novotech unterzeichnet strategische Absichtserklärung mit Hong Kong-Shenzhen Innovation and Technology Park Limited (HSITPL)

Your Recent History

USOTC
RSPI
RespireRx Pharmaceuticals (PK)
USOTC
BLEG
Branded Legacy (PK)
USOTC
TPTW
TPT Global Tech (CE)
USOTC
KEGS
1812 Brewing (PK)
USOTC
SFRX
Seafarer Exploration (PK)
USOTC
SPZI
Spooz (PK)
USOTC
ASKH
Astika (PK)
NASDAQ
FFIE
Faraday Future Intellige...
USOTC
GRLT
Grillit (PK)
NASDAQ
AGBA
AGBA
USOTC
TDRK
TideRock Companies (PK)
NASDAQ
IOVA
Iovance Biotherapeutics
USOTC
NSAV
Net Savings Link (PK)
USOTC
AFFU
Affluence (PK)
USOTC
HHSE
Hannover House (PK)
USOTC
ENZC
Enzolytics (PK)
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

United States
Company
Business
Popular
Get The App
App Store
Google Play

Support: 1-888-992-3836 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved